Is Alcon AG (ALC) a Stock to Watch After Losing -0.58% This Week?

Is Alcon AG (ALC) a Stock to Watch After Losing -0.58% This Week?

[ad_1]

Overall market sentiment has been high on Alcon AG (ALC) stock lately. ALC receives a Bullish rating from InvestorsObserver’s Stock Sentiment Indicator.

Sentiment Score - ,bullish
Alcon AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALC!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What’s Happening With ALC Stock Today?

Alcon AG (ALC) stock is trading at $69.85 as of 1:28 PM on Thursday, Jul 8, a drop of -$1.37, or -1.92% from the previous closing price of $71.22. The stock has traded between $69.77 and $70.85 so far today. Volume today is low. So far 529,540 shares have traded compared to average volume of 728,536 shares.

To see the top 5 stocks in the Medical Instruments & Supplies industry click here.

More About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Click Here to get the full Stock Score Report on Alcon AG (ALC) Stock.

[ad_2]

Source link